US 10004764 B2 - Red Blood Cell Membrane-derived Microparticles And Their Use For The Treatment Of Lung Disease - The Lens

Red Blood Cell Membrane-derived Microparticles And Their Use For The Treatment Of Lung Disease

Published: Jun 26, 2018
Earliest Priority: Nov 07 2013
Family: 4
Cited Works: 19
Cited by: 0
Cites: 8
Additional Info: Cited Works Full text

Abstract

Cell-based therapies show considerable potential as an immunomodulatory strategy for a variety of lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, bronchiolitis, acute lung injury, lung allograft rejection (acute or chronic), pulmonary fibrosis. Described herein is the development of red blood cell membrane-derived microparticles (RBC MPs), which are depleted of hemoglobin (Hb) and express phosphatidylserine on their surface, for the treatment of lung disease. Administration of RBC MPs to the lung via inhalation promotes the production of immunoregulatory cytokines (such as IL-10), and reduces inflammation and injury in the lung.

Claims

An engineered or artificial red blood cell membrane-derived microparticle (RBC MP) comprising biosynthesized oxidized stearoyl-linoleoyl-phosphatidylserine (SLPS) or dilinoleoyl-phosphatidylserine (DLPS), wherein the SLPS or DLPS is oxidized by treatment with lipoxygenases or cytochrome c on the presence of hydrogen peroxide (H₂O₂).
The engineered or artificial RBC MP of claim 1, wherein the RBC MP is about 100 to about 1000 nm in diameter.
The engineered or artificial RBC MP of claim 1, wherein the RBC MP is about 200 to about 300 nm in diameter.
The artificial RBC MP of claim 1, wherein the artificial RBC MP comprises an artificial liposome.
A composition comprising the engineered or artificial RBC MP of claim 1 and a pharmaceutically acceptable carrier.
The composition of claim 5 formulated for administration by inhalation.
The composition of claim 6, wherein the composition is formulated as a liquid aerosol for administration by inhalation.
The composition of claim 7, wherein the droplet size range of the liquid aerosol is 1-5 μm.
The composition of claim 7, wherein the droplet size range of the liquid aerosol is 1.36-3.30 μm.
A method, comprising administering to a subject the engineered or artificial red blood cell microparticles (RBC MPs) of claim 1 by inhalation.
The method of claim 10, wherein the engineered or artificial RBC MPs are administered as a liquid aerosol for inhalation.
The method of claim 10, wherein the engineered or artificial RBC MPs are administered as a dry powder for inhalation.
The method of claim 10, wherein the engineered or artificial RBC MPs are administered using a nebulizer, metered dose inhaler or dry powder inhaler.
The method of claim 10, wherein the engineered or artificial RBC MPs are about 100 to about 1000 nm in diameter.
The method of claim 14, wherein the engineered or artificial RBC MPs are about 200 to about 300 nm in diameter.